Physician profile
Marie Bui
NPI 1174757751
$7,178.54
in general payments reported to CMS, 2019-2025
30 companies · $968 in 2025
The $968 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $748 · 2021: $1,134 · 2022: $782 · 2023: $1,323 · 2024: $1,674 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,965.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,540.63 | 2019-2024 | Tecnis Simplicity, Tecnis Iol, One Series Ultra |
| Alcon Vision LLC | $1,452.22 | 2019-2025 | Clareon, Argos, Centurion |
| Bausch & Lomb Americas INC. | $863.84 | 2022-2025 | Vyzulta, Miebo, Envista Mx60 Iol |
| Rxsight INC | $442.81 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Abbvie INC. | $350.76 | 2022-2025 | |
| Allergan, INC. | $246.77 | 2020-2022 | |
| Carl Zeiss Meditec USA, INC. | $206.65 | 2021-2024 | Eq Workplace |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $202.53 | 2020-2021 | |
| Sight Sciences, INC. | $194.64 | 2019-2025 | Omni Surgical System |
| New World Medical,INC. | $191.54 | 2019-2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Glaukos Corporation | $164.66 | 2025 | Idosetr |
| Horizon Therapeutics Plc | $146.45 | 2023 | Tepezza |
| Mallinckrodt Hospital Products INC. | $143.94 | 2020-2023 | Acthar |
| Genentech USA, INC. | $126.78 | 2023 | Vabysmo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $121.52 | 2024 | Syfovre |
| Novartis Pharmaceuticals Corporation | $108.31 | 2019-2021 | |
| Harrow Eye, LLC | $104.24 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $84.31 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $57.11 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $48.70 | 2020-2022 | |
| Coopervision INC. | $25.80 | 2024 | Myday Contact Lens |
| Biotissue Holdings INC. | $24.75 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $24.08 | 2024 | Xdemvy |
| Amgen INC. | $23.73 | 2024 | Tepezza |
| Dompe US, INC. | $22.28 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.84 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Ocular Therapeutix, INC. | $18.74 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.